Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

Table 5 Comparison of features between the training and validation sets, n (%)

Characteristic	Test (n = 78)	Train (n = 182)	χ2	P value
Age, years			0.80	0.370
< 60	39 (50.00)	80 (43.96)
≥ 60	39 (50.00)	102 (56.04)
Sex			0.21	0.645
Female	37 (47.44)	92 (50.55)
Male	41 (52.56)	90 (49.45)
BMI, kg/m2			0.21	0.054
< 25	66 (84.62)	134 (73.63)
≥ 25	12 (15.38)	48 (26.37)
FAR			0.62	0.432
Low	34 (43.59)	89 (48.90)
High	44 (56.41)	93 (51.10)
ECOG			0.21	0.647
0	50 (64.10)	122 (67.03)
1	28 (35.90)	60 (32.97)
Site			0.87	0.350
Stomach	42 (53.85)	86 (47.25)
Gastric and esophageal binding	36 (46.15)	96 (52.75)
Histological			1.74	0.188
Adenocarcinoma	25 (32.05)	44 (24.18)
Other	53 (67.95)	138 (75.82)
Staging			0.77	0.379
3	27 (36.62)	53 (29.12)
4	51 (65.38)	129 (70.88)
CEA, ng/mL			3.60	0.058
< 3	39 (50.00)	68 (37.36)
≥ 3	39 (50.00)	114 (62.64)
Liver metastasis			0.59	0.441
No	54 (69.23)	114 (64.29)
Yes	24 (30.77)	68 (37.36)
Peritoneal metastasis			1.04	0.308
No	61 (78.21)	152 (83.52)
Yes	17 (21.97)	30 (16.48)
EBV status			0.00	0.971
No-infect	65 (83.33)	152 (83.52)
Infect	13 (16.67)	30 (16.48)
PD-L1 expression			0.29	0.588
CPS < 5	14 (17.95)	38 (4.40)
CPS ≥ 5	64 (82.05)	174 (95.60)
MMR status			0.00	1.000
pMMR	4 (5.13)	8 (4.40)
dMMR	74 (94.87)	174 (95.60)

FAR: Fibrinogen-to-albumin ratio; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.